Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children

Valovirta, Erkka; Jacobsen, Lars; Ljørring, Christian; Koivikko, A.; Savolainen, J.

doi:10.1111/j.1398-9995.2006.01190.x

Cited by 125 publications

(118 citation statements)

References 33 publications

(38 reference statements)

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…25,28 Five studies demonstrated significant improvement in rhinitis/ rhinoconjunctivitis scores with SLIT, compared with placebo, with moderate to strong magnitudes of effect. 33,34,[36][37][38] Four studies did not show significant improvement with SLIT, 25,26,29,32 and 1 of these favored placebo. 26 The strength of evidence is moderate that SLIT improves rhinitis symptoms.…”

Section: Rhinitismentioning

confidence: 99%

“…[25][26][27][28][29][32][33][34][35][36][37][38] One-half of the studies evaluated dust mite allergens. 25,26,[32][33][34]38 Risk of bias was low in 4 studies, 27,29,32,34 medium in 6 studies, 26,33,[35][36][37][38] and high in 2 studies. 25,28 Five studies demonstrated significant improvement in rhinitis/ rhinoconjunctivitis scores with SLIT, compared with placebo, with moderate to strong magnitudes of effect.…”

Section: Rhinitismentioning

confidence: 99%

“…[22][23][24][32][33][34][35]37,38 Seven studies evaluated dust mite allergen. [22][23][24][32][33][34]38 The SLIT-treated children in the placebo-controlled studies demonstrated moderate to strong improvement in asthma symptoms.…”

Section: Asthmamentioning

confidence: 99%

See 2 more Smart Citations

Allergen-Specific Immunotherapy for Pediatric Asthma and Rhinoconjunctivitis: A Systematic Review

Kim¹,

Lin²,

et al. 2013

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVE: Subcutaneous immunotherapy (SCIT) is approved in the United States for the treatment of pediatric asthma and rhinitis; sublingual immunotherapy (SLIT) does not have regulatory approval but is used in clinical practice. The objective of this study was to systematically review the evidence regarding the efficacy and safety of SCIT and SLIT for the treatment of pediatric asthma and allergic rhinoconjunctivitis. METHODS:Two independent reviewers selected articles for inclusion, extracted data, and graded the strength of evidence for each clinical outcome. All studies were randomized controlled trials of children with allergic asthma or rhinoconjunctivitis treated with SCIT or an aqueous formulation of SLIT. Data sources were Medline, Embase, LILACS, CENTRAL, and the Cochrane Central Register of Controlled Trials through May 2012. RESULTS:In 13 trials, 920 children received SCIT or usual care; in 18 studies, 1583 children received SLIT or usual care. Three studies compared SCIT with SLIT head-to-head in 135 children. The strength of evidence is moderate that SCIT improves asthma and rhinitis symptoms and low that SCIT improves conjunctivitis symptoms and asthma medication scores. Strength of evidence is high that SLIT improves asthma symptoms and moderate that SLIT improves rhinitis and conjunctivitis symptoms and decreases medication usage. The evidence is low to support SCIT over SLIT for improving asthma or rhinitis symptoms or medication usage. Local reactions were frequent with SCIT and SLIT. There was 1 report of anaphylaxis with SCIT.CONCLUSIONS: Evidence supports the efficacy of both SCIT and SLIT for the treatment of asthma and rhinitis in children. Pediatrics

show abstract

Section: Rhinitismentioning

confidence: 99%

Section: Rhinitismentioning

confidence: 99%

See 1 more Smart Citation

Allergen-Specific Immunotherapy for Pediatric Asthma and Rhinoconjunctivitis: A Systematic Review

Kim¹,

Lin²,

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The duration of SLIT courses varied from 3 months (minimum duration) to 3 years (maximum duration). The administration regimen was preseasonal in three studies (27,32,44), co-seasonal in three (15,42,47), and continuous in eight trials (30,35,38,39,41,43,46,54), despite the allergen was seasonal. In the remaining 27 trials the adopted regimen was precoseasonal.…”

Section: Literature Analysismentioning

confidence: 99%

Administration regimens for sublingual immunotherapy to pollen allergens: What do we know?

Lombardi

Incorvaia²,

Braga

et al. 2009

Allergy

View full text Add to dashboard Cite

The modalities of administration of sublingual immunotherapy (SLIT), including dosing, build‐up phase, duration of the treatment, and frequency of the maintenance dose are largely variable. In the case of pollen (SLIT), the complexity increases, since preseasonal, coseasonal and pre‐coseasonal regimens can be used. The administration regimens are of relevance from a practical point of view, but can also have economic implications. We review herein the available literature (randomized double blind controlled studies) on pollen SLIT, in order to derive experimentally‐supported suggestions about the regimens of administration that should be preferred.

show abstract

“…Eighteen months of SLIT with tree pollen extract provided dose-dependent benefits in terms of significantly reduced symptoms and medication use. (Valovirta E et al, 2006) Two adequately powered, well-designed double blind placebo controlled (DBPC) www.intechopen.com randomized controlled trial (RCTs) have now been published, both showing a clear effect of allergen tablets in childhood. A statistically significant reduction in rhinitis symptoms (28%) and medication (64%) score was shown during the pollen season in 114 children receiving active grass allergen tablets (with 15g Phl p 5) compared with 120 children in the placebo group.…”

Section: Clinical Efficacymentioning

confidence: 99%

Clinical Implications and Facts About Allergic Rhinitis (AR) in Children

Živković¹,

Cerović²,

Djuric-Filipovic³

et al. 2012

Allergic Rhinitis

View full text Add to dashboard Cite

Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children

Abstract: SLIT with tree pollen extract provided dose-dependent benefits in tree pollen-allergic children in terms of significantly reduced symptoms and medication use. The treatment was well tolerated.

Cited by 125 publications

References 33 publications

Allergen-Specific Immunotherapy for Pediatric Asthma and Rhinoconjunctivitis: A Systematic Review

Allergen-Specific Immunotherapy for Pediatric Asthma and Rhinoconjunctivitis: A Systematic Review

Administration regimens for sublingual immunotherapy to pollen allergens: What do we know?

Clinical Implications and Facts About Allergic Rhinitis (AR) in Children

Contact Info

Product

Resources

About